NDA 022305 · Niagara Pharms
Pur-Wash
Purified Water · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Sep 1, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
134
27 Phase 3, 16 recruiting
FAERS reports
679
461 serious, 66 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 9, 2025.
Use For cleansing the eye to help relieve irritation or burning by removing loose foreign material
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 1, 2011 Original approval · Type 5 - New Formulation or New Manufacturer ReviewSummary ReviewLetter
1 products under this application
- PUR-WASH · PURIFIED WATER 98.3% · SOLUTION, OPHTHALMIC · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Purified Water" as an intervention, any sponsor and status, largest first.
- Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) InfectionPivotal-lookingCompleted
CONRADAcademic, hospital or other
NCT01386294 · 2,059 participants · Start Oct 2011 · Primary completion Aug 2014
Drug: Tenofovir gel; Universal placebo gel · For: HIV Prevention
Sites: Pietermaritzburg, South Africa; Cape Town, South Africa; Diepkloof, South Africa · 9 sites in all
- Health Impact of Treating and Safely Storing Shallow Tubewell Drinking WaterPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01350063 · 1,800 participants · Start Feb 2011 · Primary completion May 2012
Drug: Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab) · For: Diarrhoeal Disease
Sites: Mymensingh, Bangladesh
- Pre-operative Aqueous Antiseptic Skin Solutions in Open FracturesPivotal-lookingCompleted
University of Maryland, BaltimoreAcademic, hospital or other
NCT03385304 · 1,638 participants · Start Apr 8, 2018 · Primary completion Oct 19, 2021
Drug: 10% povidone-iodine (1% free iodine) in purified water; 4% chlorhexidine gluconate (CHG) in purified water · For: Surgical Site Infection; Unplanned Fracture-Related Reoperation; Open Appendicular Fracture
Sites: Phoenix, Arizona; Tucson, Arizona; San Francisco, California · 15 sites in all
- Adaptive COVID-19 Treatment Trial 3 (ACTT-3)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04492475 · 969 participants · Start Aug 5, 2020 · Primary completion Dec 21, 2020
Drug: Interferon beta-1a; Remdesivir · For: COVID-19
Sites: Birmingham, Alabama; Fresno, California; La Jolla, California · 64 sites in all
- Phase 2B/3 Double-blinded Placebo-controlledPivotal-lookingCompleted
Evofem Inc.Industry
NCT03107377 · 860 participants · Start Nov 3, 2017 · Primary completion Aug 22, 2019
Drug: EVO100; Placebo · For: Chlamydia Trachomatis Infection
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 50 sites in all
- Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk SyndromePivotal-lookingStatus unknown
Beijing Tiantan HospitalAcademic, hospital or other
NCT04492241 · 800 participants (planned) · Start Jul 5, 2021 · Primary completion Dec 31, 2023
Drug: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution; Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution · For: Motoric Cognitive Risk Syndrome; Mild Cognitive Impairment; Aging and 1 more
Sites: Beijing, China
- Non-specific Effects of Rabies VaccinePivotal-lookingCompleted
Ross University School of Veterinary MedicineAcademic, hospital or other
NCT03656198 · 546 participants · Start Aug 29, 2018 · Primary completion Jul 27, 2020
Drug: Rabivax-S; Sterile Water Injection · For: Influenza-like Illness; Upper Respiratory Disease; Diarrhea and 1 more
Sites: Basseterre, Saint Kitts and Nevis
- Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in MaliPivotal-lookingCompleted
U.S. Army Medical Research and Development CommandFederal agency
NCT00460525 · 400 participants · Start May 2007 · Primary completion Jul 2009
Drug: FMP2.1/AS02A; Rabies Vaccine · For: Plasmodium Falciparum Malaria
Sites: Bamako, Mali
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue44
- pain38
- nausea36
- dyspnoea34
- off label use32
- drug ineffective30
- vomiting30
- headache28
- malaise28
- diarrhoea27
- pyrexia27
- death24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 8 |
| 2010 | 11 |
| 2011 | 10 |
| 2012 | 15 |
| 2013 | 7 |
| 2014 | 32 |
| 2015 | 40 |
| 2016 | 23 |
| 2017 | 22 |
| 2018 | 28 |
| 2019 | 26 |
| 2020 | 17 |
| 2021 | 46 |
| 2022 | 80 |
| 2023 | 75 |
| 2024 | 56 |
| 2025 | 74 |
| 2026 | 86 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effects of pharmaceutical excipients on small intestinal transit.
Adkin DA, Davis SS, Sparrow RA, et al. · Br J Clin Pharmacol 1995 · Clinical Trial, Controlled Clinical Trial
- A MULTICENTER, RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE EFFECT OF CETYLPYRIDINIUM CHLORIDE (CPC) MOUTHWASH AND ON-DEMAND AQUEOUS CHLORINE DIOXIDE MOUTHWASH ON SARS-COV-2 VIRAL TITER IN PATIENTS WITH MILD COVID-19.
Onozuka D, Konishi K, Takatera S, et al. · J Evid Based Dent Pract 2024 · Randomized Controlled Trial, Multicenter Study
- [Evaluation of tixocortol pivalate-neomycin combination versus ++a placebo excipient in acute rhinopharyngitis in children].
Reinert P, Narcy P, Paliwoda A, et al. · Ann Pediatr (Paris) 1991 · Clinical Trial, Randomized Controlled Trial
- Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation.
Sirisuth N, Augsburger LL, Eddington ND · Biopharm Drug Dispos 2002 · Clinical Trial, Randomized Controlled Trial
- Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers.
Gubbins PO, McConnell SA, Gurley BJ, et al. · Pharmacotherapy 2004 · Clinical Trial, Randomized Controlled Trial
- The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption.
Adkin DA, Davis SS, Sparrow RA, et al. · Pharm Res 1995 · Clinical Trial, Randomized Controlled Trial
Sponsor: Niagara Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.